Barclays
NXTC icon

Barclays’s NextCure NXTC Stock Holding History

Barclays’s Portfolio NXTC Stock Details NXTC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.16K Buy
5,726
+100
+2% +$739 ﹤0.01% 4706
2026
Q1 		$60.1K Hold
5,626
– – ﹤0.01% 4246
2025
Q4 		$79.8K Hold
5,626
– – ﹤0.01% 4637
2025
Q3 		$33K Sell
5,626
-1
-0% -$5 ﹤0.01% 4863
2025
Q2 		$31.1K Hold
5,627
– – ﹤0.01% 4780
2025
Q1 		$32.4K Hold
5,627
– – ﹤0.01% 4704
2024
Q4 		$52.1K Hold
5,627
– – ﹤0.01% 4752
2024
Q3 		$92.5K Hold
5,627
– – ﹤0.01% 4590
2024
Q2 		$107K Sell
5,627
-2
-0% -$39 ﹤0.01% 3871
2024
Q1 		$151K Hold
5,629
– – ﹤0.01% 4258
2023
Q4 		$77K Hold
5,629
– – ﹤0.01% 4698
2023
Q3 		$87.1K Hold
5,629
– – ﹤0.01% 3643
2023
Q2 		$122K Hold
5,629
– – ﹤0.01% 3489
2023
Q1 		$100K Sell
5,629
-1
-0% -$19 ﹤0.01% 4177
2022
Q4 		$95.3K Sell
5,630
-44
-0.8% -$1.01K ﹤0.01% 4253
2022
Q3 		$187K Hold
5,674
– – ﹤0.01% 3248
2022
Q2 		$320K Sell
5,674
-400
-7% -$20.9K ﹤0.01% 3156
2022
Q1 		$354K Buy
6,074
+78
+1% +$4.88K ﹤0.01% 3106
2021
Q4 		$432K Sell
5,996
-201
-3% -$16.8K ﹤0.01% 3265
2021
Q3 		$501K Buy
6,197
+2,992
+93% +$262K ﹤0.01% 3198
2021
Q2 		$309K Buy
3,205
+32
+1% +$3.27K ﹤0.01% 3342
2021
Q1 		$381K Sell
3,173
-456
-13% -$66K ﹤0.01% 3349
2020
Q4 		$474K Sell
3,629
-239
-6% -$30.9K ﹤0.01% 3260
2020
Q3 		$407K Buy
3,868
+3,040
+367% +$374K ﹤0.01% 3381
2020
Q2 		$213K Buy
828
+341
+70% +$130K ﹤0.01% 4021
2020
Q1 		$216K Sell
487
-803
-62% -$429K ﹤0.01% 4240
2019
Q4 		$872K Buy
1,290
+1,136
+738% +$570K ﹤0.01% 3801
2019
Q3 		$56K Sell
154
-676
-81% -$220K ﹤0.01% 5856
2019
Q2 		$138K Buy
+830
New +$173K ﹤0.01% 5434

Other funds holding NXTC

IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
VA
Verdad Advisers Boston, Massachusetts $104M AUM
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return

Barclays's NXTC Position: Q2 2026 in Review

Barclays increased its NextCure (NXTC) stake by 1.8% in Q2 2026, buying an estimated $739 and bringing the position to 5,726 shares worth $9.16K. The position accounts for ﹤0.01% of the portfolio, ranked #4706.

Barclays first reported a position in NXTC in Q2 2019 and has held it in 29 quarters since. The position peaked at $872K in Q4 2019. 30 funds tracked by Wall St. Rank hold NXTC as of Q2 2026.

  • Barclays held 5,726 shares of NextCure worth $9.16K as of Q2 2026.
  • Barclays bought 100 NextCure shares in Q2 2026, an estimated $739.
  • NextCure made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #4706 holding.
  • Barclays first reported a position in NextCure in Q2 2019 and has held it in 29 quarters since.
  • Barclays's NextCure position peaked at $872K in Q4 2019.
  • 30 funds tracked by Wall St. Rank held NextCure as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.